Phathom Pharmaceuticals Inc (PHAT) Stock Price, Quote & News

Company Profile

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for t...

Industry: Biotechnology

Sector: Healthcare

Phone: 877 742 8466

Website: www.phathompharma.com

Address:

100 Campus Drive, Suite 102, Florham Park, United States

fgggggggg Mar. 16 at 12:36 PM

$PHAT also interesting the pre market has been trading in the 10s of thousands of shares the past week or so. This was historically a few hundred shares

0 · Reply

fgggggggg Mar. 16 at 11:28 AM

$PHAT im pretty sure millennium doubled their position in PHAT. Check the recent filing.

0 · Reply

HedgeFollow Mar. 16 at 11:00 AM

▫️▫️▫️▫️▫️▫️ 🔹𝗗𝗼𝘂𝗯𝗹𝗲 𝗗𝗼𝘄𝗻𝘀 by 5-star Hedge Funds🔹 As per latest filings last week: • Valiant Capital just DOUBLED their $CORZ position • Millennium Management DOUBLED $PHAT stake Source: https://hedgefollow.com/stocks/CORZ

0 · Reply

stocksUP59 Mar. 13 at 6:24 PM

$PHAT Pretty nice chart. Q1 plan resets don't seem to be too major of an impact going forward... Prescription volume rebounding quickly and should see new records in the coming weeks. #BULLISH

3 · Reply

longshot45 Mar. 13 at 3:45 PM

$PHAT You guys may very well get your 9.99 today.

1 · Reply

bioland Mar. 13 at 1:20 AM

$PHAT Still no covering at all...I guess we're headed lower tomorrow. Unreal.

1 · Reply

GSTX7 Mar. 12 at 10:20 PM

$PHAT Same. What a tease...

1 · Reply

Walleyeslayer Mar. 12 at 7:56 PM

$PHAT dang my 9.99 bid has not filled.

1 · Reply

Randy_Lahey_Trevor_Corey Mar. 12 at 7:45 PM

$PHAT 9s definitely in play

1 · Reply

Joe_90_ Mar. 12 at 2:48 PM

$PHAT bought another 250 will continue to add

0 · Reply

Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Feb 26, 2026, 5:09 PM EST - 17 days ago

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript

Feb 26, 2026, 7:00 AM EST - 18 days ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Feb 23, 2026, 8:00 AM EST - 21 days ago

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Feb 17, 2026, 8:00 AM EST - 27 days ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026

Feb 5, 2026, 8:00 AM EST - 5 weeks ago

Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026

Jan 7, 2026, 10:33 PM EST - 2 months ago

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

Jan 7, 2026, 4:05 PM EST - 2 months ago

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jan 7, 2026, 4:01 PM EST - 2 months ago

Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Nov 21, 2025, 4:03 PM EST - 4 months ago

Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth

Nov 4, 2025, 8:00 AM EST - 4 months ago

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Oct 30, 2025, 1:26 PM EDT - 4 months ago

Phathom Pharmaceuticals, Inc. (PHAT) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 7:00 AM EDT - 4 months ago

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 25, 2025, 9:59 AM EDT - 5 months ago

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

Oct 23, 2025, 8:00 AM EDT - 5 months ago

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

Oct 20, 2025, 8:00 AM EDT - 5 months ago

Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

Oct 6, 2025, 1:29 PM EDT - 5 months ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN ARKG AZN BIIB BMY

Oct 6, 2025, 8:00 AM EDT - 5 months ago

Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

Aug 20, 2025, 8:00 AM EDT - 7 months ago

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing

Aug 7, 2025, 10:51 PM EDT - 7 months ago

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 6:59 AM EDT - 7 months ago

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 28, 2025, 8:00 AM EDT - 8 months ago

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

Jun 25, 2025, 4:54 AM EDT - 9 months ago

Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism

Jun 23, 2025, 4:15 PM EDT - 9 months ago

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 23, 2025, 7:59 AM EDT - 9 months ago

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

SAGE

Jun 16, 2025, 8:00 AM EDT - 9 months ago

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

Jun 10, 2025, 10:08 AM EDT - 9 months ago

Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy

Jun 6, 2025, 12:27 PM EDT - 10 months ago

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

May 1, 2025, 12:09 PM EDT - 11 months ago

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript

May 1, 2025, 7:00 AM EDT - 11 months ago

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

ITCI

Apr 28, 2025, 7:59 AM EDT - 11 months ago

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting

Apr 23, 2025, 8:00 AM EDT - 11 months ago

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

Apr 17, 2025, 8:00 AM EDT - 11 months ago

Frazier Life Sciences Appoints Aditya Kohli to Partner

HLVX

Apr 16, 2025, 8:00 AM EDT - 11 months ago

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

CDTX

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces Leadership Succession

Mar 31, 2025, 7:59 AM EDT - 1 year ago

Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)

Mar 6, 2025, 12:13 PM EST - 1 year ago

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 24, 2025, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

Jan 29, 2025, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

Dec 11, 2024, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

Nov 10, 2024, 3:54 AM EST - 1 year ago

Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call Transcript

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

Oct 27, 2024, 12:00 PM EDT - 1 year ago

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

Aug 10, 2024, 2:52 PM EDT - 1 year ago

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 18, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

fgggggggg Mar. 16 at 12:36 PM

$PHAT also interesting the pre market has been trading in the 10s of thousands of shares the past week or so. This was historically a few hundred shares

0 · Reply

fgggggggg Mar. 16 at 11:28 AM

$PHAT im pretty sure millennium doubled their position in PHAT. Check the recent filing.

0 · Reply

HedgeFollow Mar. 16 at 11:00 AM

0 · Reply

stocksUP59 Mar. 13 at 6:24 PM

$PHAT Pretty nice chart. Q1 plan resets don't seem to be too major of an impact going forward... Prescription volume rebounding quickly and should see new records in the coming weeks. #BULLISH

3 · Reply

longshot45 Mar. 13 at 3:45 PM

$PHAT You guys may very well get your 9.99 today.

1 · Reply

bioland Mar. 13 at 1:20 AM

$PHAT Still no covering at all...I guess we're headed lower tomorrow. Unreal.

1 · Reply

GSTX7 Mar. 12 at 10:20 PM

$PHAT Same. What a tease...

1 · Reply

Walleyeslayer Mar. 12 at 7:56 PM

$PHAT dang my 9.99 bid has not filled.

1 · Reply

Randy_Lahey_Trevor_Corey Mar. 12 at 7:45 PM

$PHAT 9s definitely in play

1 · Reply

Joe_90_ Mar. 12 at 2:48 PM

$PHAT bought another 250 will continue to add

0 · Reply

JP2024 Mar. 12 at 1:50 PM

$PHAT seems like the macro issues are dragging us down even more … man its tough to be in market when its volatile buffet said sit back but easy when youre sitting on billions .. not thousands

1 · Reply

TheFlyingDutchmann Mar. 11 at 8:20 PM

$PHAT lol at the price action today. Nice hammer on the chart though. Could this be our bottom?

1 · Reply

Quantumup Mar. 11 at 8:06 PM

Raymond James (a/o 3/9) reiterated $EPRX at a Strong Buy rating and an $18 PT. $REGN - SNY $APGE BMY $TAK AZN - AMGN $PHAT Raymond James said in its note: Following our recent initiation of coverage and investor discussions thereafter, we are circling back to recap our thesis on EPRX, which we believe has among the best 2026 risk/reward setups in our coverage universe into Phase 2b RESOLVE data for EP-104GI in EoE expected in 2H26. Reiterate Strong Buy. Here's what else Raymond James had to say:

0 · Reply

bioland Mar. 11 at 8:03 PM

$PHAT Textbook accumulation today.

0 · Reply

LadsAndGents Mar. 11 at 4:08 PM

$PHAT dip is exiting for me enough to start with 1K shares

1 · Reply

bioland Mar. 11 at 2:42 PM

$PHAT Shorts can suck a phat dick.

2 · Reply

Longboardsoul Mar. 11 at 12:13 PM

$PHAT overpriced Rolaids

0 · Reply

Randy_Lahey_Trevor_Corey Mar. 10 at 2:59 PM

$PHAT management ruined momentum, buncha fuckin tards

2 · Reply

Randy_Lahey_Trevor_Corey Mar. 9 at 8:10 PM

$PHAT need $20 ooof

0 · Reply

steven1x Mar. 8 at 3:50 PM

$PHAT what’s next

2 · Reply

GSTX7 Mar. 7 at 1:18 AM

$PHAT Everybody put a buy order at 9.99 and let's defend! I'll set a Phat one at that price.

0 · Reply

StardustTrader Mar. 6 at 7:57 PM

$PHAT mid 10s are a gift but if they dont hold, well retest 7-8. Wouldnt recommend waiting for that. Picking up a small allocation in mid 10s.

0 · Reply

Market Cap	817.15M
Revenue (ttm)	175.11M
Net Income (ttm)	-221.25M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-126.35%
Debt to Equity Ratio	-0.48

Volume	1,258,400
Avg Vol	1,156,980
Day's Range	N/A - N/A
Shares Out	78.80M
Stochastic %K	19%
Beta	0.51
Analysts	Strong Sell
Price Target	$23.50